Phil Jakeman
Chief Executive Officer Matchbio
Phil has spent over 15 years in the immunotherapy field across academia, venture capital and early stage biotech, where he has founded multiple biotech companies with a cell therapy focus
Seminars
Wednesday 2nd December 2026
Evidence – Exploring the CombiCell Platform to Provides a Clinically Relevant Antigen-Biology Layer for Immunotherapy Discovery
4:20 pm
- Immunotherapy response is governed by antigen density thresholds, not binary target presence – yet discovery still relies on cell lines that sit far above clinical densities, hiding the low-density and relapse conditions where CAR-T, TCEs and multi-specifics actually fail.
- CombiCell allows display of one or more targets on cells at precise, tunable densities in minutes rather than months – spanning the full clinical range, free of genetic drift, and reaching the ultra-low densities beyond the limits of flow cytometry.
- This transforms antigen density into a controllable experimental variable across modalities, grounding in vitro discovery R&D in clinical relevant target densities
Wednesday 2nd December 2026
Insights Exchange – What Biological Features Are Still Missing From Today’s Tumour Models?
5:00 pm
- Which aspects of the tumour microenvironment remain most difficult to capture?
- How can advanced models be made more scalable and reproducible?
- What innovations will have the biggest impact on model relevance over the next five years?
- Audience Q&As
